Five Risks Buried in Pfizer's 8.7x Forward Multiple

Pfizer's loss-of-exclusivity exposure for 2025-2030 is one of the heaviest in big pharma. Eliquis loses US exclusivity in 2028. Ibrance comes off in 2027. Xtandi (the Astellas partnership) faces formulation challenges before its 2028 LOE. Inlyta begins generic erosion in 2025. The cumulative revenue at risk over the period is roughly $20-25 billion, depending on how aggressively biosimilar entry materialises.

The pipeline that needs to backfill this revenue is real but heavily weighted to oncology and obesity, neither of which has produced a confirmed mega-blockbuster in the past 24 months. The Seagen acquisition in 2023 was meant to be the pipeline anchor; the integration has gone reasonably well but the absolute revenue contribution is still ramping.

The LOE risk is not new. It is the most-discussed risk in pharma analyst notes. The question is whether the multiple already reflects it. We argue not fully; the 8.7x forward multiple is roughly in line with peers facing smaller LOE exposure.

Pfizer's obesity pipeline is the single biggest catalyst the bull case rests on. The two oral GLP-1 candidates (danuglipron and a follow-on) faced setbacks in mid-stage trials and the development program was scaled back in 2024. Pfizer remains in the obesity space but is no longer credible as a near-term challenger to the Eli Lilly and Novo Nordisk leadership position.

The oncology advance referenced in this week's news flow is the more concrete near-term contributor. Vyndamax cash flow visibility extension is genuine but not transformational; the franchise is too small to anchor the bull case alone.

Without the obesity catalyst, Pfizer's pipeline is competent rather than exciting. That is the problem with the multiple. A 6.6% dividend with no transformational pipeline upside trades closer to a 9-10x forward multiple than to the 12-13x where the bull case lives.

The 6.6% dividend yield is the headline. The coverage math is the substance. Pfizer's annualised dividend obligation is roughly $9.7 billion. Trailing twelve-month free cash flow has been roughly $9-11 billion in the post-COVID years. That is coverage of roughly 1.0x to 1.1x.

That coverage ratio is not crisis-level but it is not safe either. Big pharma dividend safety historically benchmarks at 1.4x to 1.6x FCF coverage. Pfizer is materially below the safe benchmark and management has reiterated commitment to the dividend at every quarterly call.

The last time a major pharma dividend was cut was Bristol-Myers in 2009 during the post-Plavix LOE cycle. The pattern was the same: tight coverage for several years, management commitment to defend the dividend, eventual capitulation when the LOE wave compressed cash flow further.

We are not predicting a dividend cut. We are noting that the coverage is tighter than the 6.6% yield implies. If FCF compresses 15-20% over the next 24 months as the LOE wave intensifies, the math gets uncomfortable.

Pfizer's capital allocation through the post-COVID cycle has been controversial. The Seagen acquisition for $43 billion was strategically defensible but timed at the absolute peak of biotech M&A multiples. The Arena Pharmaceuticals deal in 2022 has not delivered the expected pipeline contribution. The smaller bolt-on deals have been less consequential.

The contrast with Eli Lilly's capital deployment through the same period is sharp. Lilly invested aggressively in obesity and Alzheimer's manufacturing capacity that is now coming online and producing the explosive revenue trajectory. Pfizer invested in a different mix that has not produced the same returns.

This is not an accusation. Different management teams made different bets in similar environments. The bet that Pfizer made was less successful by results. The market has priced that delta into the relative multiples.

For Pfizer to re-rate from 8.7x forward to the 11-12x range that would deliver a meaningful equity return, three things need to happen. The LOE wave needs to come in better than feared. The pipeline needs to deliver one or two near-blockbusters. The capital allocation track record needs to improve.

None of those are impossible. None are zero-probability. But they all have to happen, not just one of them. That is the conditional probability problem with deep value pharma. The 6-7% dividend yield is the carry for waiting. The waiting can be long.

The historical parallel is Merck in 2009-2014, when the stock spent five years in the 9-11x forward range while the post-Vioxx pipeline rebuilt. The eventual re-rate when Keytruda arrived was sharp. The waiting was painful. Pfizer is in roughly year three of a similar cycle. We are not yet at the keytruda-equivalent moment.